Possible synthetic lethal interactions may be produced in patients with pancreatic cancer using the new targeted therapies, ATM or ATR inhibitors, as ATM and ATR are key participants in DNA repair [54]. This evidence concerns the gene ATM and familial pancreatic carcinoma.